Extended Data Fig. 2: Changes in FVC after 12 weeks of treatment with rentosertib. | Nature Medicine

Extended Data Fig. 2: Changes in FVC after 12 weeks of treatment with rentosertib.

From: A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Extended Data Fig. 2

a-b) Changes in forced vital capacity (FVC) ± 95% CI after 12 weeks of treatment compared to baseline excluding n = 1 patient from the placebo group and n = 1 patient from the rentosertib 30 mg QD group who exhibited >600 mL difference between screening and baseline FVC measurements, making uncertain the baseline FVC values in those patients. Absolute change in FVC ± 95% CI (a) and absolute change in FVC ± 95% CI ANCOVA Model with Multiple Imputation assuming missing at random (MAR) (b). (c) Absolute change in FVC (% Predicted) ± SE, ANCOVA Model with Multiple Imputation assuming MAR. (d) Percentage change in FVC ± SE, ANCOVA Model with Multiple Imputation assuming MAR. (e) Change in percent predicted FVC ± SD.

Back to article page